|
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene transcripts as potential diagnostic markers for allergic contact dermatitis.
|
16033404 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Thus, these features should be considered in the design of future clinical studies aimed at testing ASNase efficacy in AML patients.
|
31044436 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is an indispensable component of the chemotherapeutic treatment of acute lymphoblast leukaemia (ALL) and acute myeloid leukaemia (AML).
|
29159986 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.
|
28224619 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Importantly, both ASNS gene and protein expression were significantly lower in -7 AML cell lines, suggesting that haploinsufficiency of <i>ASNS</i> might induce sensitivity to L-Asp in AMLs.
|
29299118 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
|
26154683 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
|
23016580 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
Biomarker
|
disease |
BEFREE |
The knockdown of the SLC1A5 high-affinity transporter for glutamine induces apoptosis and inhibits tumor formation in a mouse AML xenotransplantation model. l-asparaginase (l-ase) is an anticancer agent also harboring glutaminase activity.
|
24014241 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.180 |
GeneticVariation
|
disease |
BEFREE |
Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
|
20804919 |
2010 |
|
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic leukemia.
|
30917738 |
2020 |
|
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase (L-Asp)-associated thromboembolisms are serious complications in pediatrics patients with acute lymphoblastic leukemia (ALL), especially at ≥10.0 years old, but the pathogenesis remains to be clarified.
|
31556233 |
2020 |
|
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
OS tends to improve with PI protocols that include L-asparaginase in AYA ALL, suggesting that therapy protocol is critical in the treatment performance of this group.
|
31612474 |
2020 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
|
31556233 |
2020 |
|
Adult Acute Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase (L-Asp)-associated thromboembolisms are serious complications in pediatrics patients with acute lymphoblastic leukemia (ALL), especially at ≥10.0 years old, but the pathogenesis remains to be clarified.
|
31556233 |
2020 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the results showed that chemical modification with carboxymethyl dextran brings about improvement of biochemical properties through several changes in the structural attributes of l-asparaginase and might enhance its applicability in the treatment of childhood leukemia.
|
31821805 |
2020 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic leukemia.
|
30917738 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
L-asparaginase is one such important enzyme that has potent applications in cancer therapy and food industry.
|
31215369 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.
|
30634463 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancer cells reduce the expression of l-asparaginase leading to their elimination.
|
30993718 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
L-asparaginase is a promising enzyme that has a wide range of significant applications including cancer therapy and starchy food industries.
|
31537817 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on a literature review and on their personal experience, CRASH and CARG were considered feasible toxicity prediction tools, appropriate for implementation in routine clinical practice, with a potentially high impact in optimizing therapy selection for elderly patients with cancer.
|
30266308 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that ASNase stimulates aspartate and glutamate consumptions, and their refilling through SLC1A3 promotes cancer cell proliferation.
|
31523835 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested ASNase wild-type (ASNase<sup>WT</sup>) and its glutaminase-deficient Q59L mutant (ASNase<sup>Q59L</sup>) and found that ASNase glutaminase activity contributed to durable anticancer activity against xenografts of the ASNS-negative Sup-B15 leukemia cell line in NOD/SCID gamma mice, whereas asparaginase activity alone yielded a mere growth delay.
|
31209181 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-asparaginase is a valuable protein therapeutic drug utilized for the treatment of leukemia and lymphomas.
|
30426897 |
2019 |